Table 1.
Demographic and clinical data for the 150 HIV-infected women from the HERS cohort included in the current analysis based on HPgV RNA status.
| Characteristic | HPgV RNA negative (N = 80) |
HPgV RNA positive (N = 70) |
P value |
|---|---|---|---|
| Mean age in years (SD) | 39.3 (6.1) | 34.7 (5.4) | <0.001 |
| Race (%) | 0.025 | ||
| Black | 63 (78.8%) | 40 (57.1%) | |
| White | 9 (11.3%) | 16 (22.9%) | |
| Hispanic | 7 (8.7%) | 13 (18.6%) | |
| Native American/Asian/Other | 1 (1.2%) | 1 (1.4%) | |
| Study site | <0.001 | ||
| NY | 17 (21.3) | 14 (20.0) | |
| MI | 35 (43.7) | 12 (17.1) | |
| MD | 28 (35.0) | 24 (34.3) | |
| RI | 0 | 20 (28.6) | |
| Sexual and drug use behaviors | |||
| IDU since 1985 (%) | 75 (93.8%) | 61 (87.1%) | 0.165 |
| IDU in previous 6 months (%) | 29 (36.3%) | 30 (42.9%) | 0.409 |
| ≥5 sex partners in past 6 months (%) | 19 (23.8%) | 18 (25.7%) | 0.781 |
| Ever had sex with male IDU (%) | 70 (87.5%) | 61 (88.4%) | 0.866 |
| Ever had sex with partner known/suspected HIV+ (%) | 43 (53.8%) | 43 (62.3%) | 0.291 |
| Ever had sex for money or drugs (%) | 35 (43.8%) | 34 (48.6%) | 0.555 |
| Male sex partners in previous 6 months (%) | 0.652 | ||
| 0 | 27 (33.7%) | 20 (28.6%) | |
| 1–10 | 51 (63.8%) | 49 (70.0%) | |
| >10 | 2 (2.5%) | 1 (1.4%) | |
| Currently using hormonal contraceptives (%) | 1 (1.3%) | 3 (4.3%) | 0.340 |
| Currently using condoms (%) [102 sexually active] | 34 (64.2%) | 37 (74.0%) | 0.281 |
| Ever been pregnant (%) | 74 (92.5%) | 67 (95.7%) | 0.504 |
| Currently pregnant (%) | 1 (1.3%) | 0 | 1.0 |
| Currently using alcohol (%) | 49 (61.3%) | 40 (57.1%) | 0.609 |
| CD4 count (Median, IQR) | 447 (286–623) | 421 (311–577) | 0.531 |
| Log viral load (SD) | 3.0 (0.86) | 3.2 (0.80) | 0.105 |
| Non-HAART antiretroviral therapy* | 24 (30.0%) | 24 (34.3%) | 0.575 |
| All-cause mortality (%) | 0.598 | ||
| 1993 – 1996 | 12 (15.0%) | 7 (10.0%) | |
| 1997 – 2000 | 10 (12.5%) | 11 (15.7%) | |
| HBsAg positive (%) | 2 (3.2%) | 3 (5.4%) | 0.665 |
P-values for potential associations between HPgV status and categorical characteristics were determined by chi-square test or by Fisher’s exact test if any expected cell count was <5. For continuous characteristics, p-values were determined by t tests if normally distributed and by Wilcoxon rank-sum test if not normally distributed.
SD – standard deviation; IDU – injection drug use; HBsAg – Hepatitis B virus surface antigen; NS – not significant
*
None of the women were on HAART at HERS enrollment.